You haven't searched anything yet.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.
Full Time
$234k-293k (estimate)
04/25/2024
05/08/2024
alnylam.com
CAMBRIDGE, MA
1,000 - 3,000
2002
Public
MARK JOHNSON
$200M - $500M
Pharmaceutical
Alnylam is a biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases.
The following is the career advancement route for Associate Director, Clinical Operations positions, which can be used as a reference in future career path planning. As an Associate Director, Clinical Operations, it can be promoted into senior positions as a Medical Director that are expected to handle more key tasks, people in this role will get a higher salary paid than an ordinary Associate Director, Clinical Operations. You can explore the career advancement for an Associate Director, Clinical Operations below and select your interested title to get hiring information.